

Risk Assessment and Control in Medical Investment, Merger, and Acquisition

Feng Qian*

Shanghai Invisk Medical Technology Co., Ltd., Shanghai 200082, China

*Corresponding author: Feng Qian, jyc879399@163.com

Copyright: © 2024 Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), permitting distribution and reproduction in any medium, provided the original work is cited.

Abstract: The risk assessment and control of medical investment, merger, and acquisition are crucial topics within the medical industry, encompassing various aspects of investment, merger, and acquisition within this sector. The process primarily targets the unique nature and associated risks of the medical industry, focusing on effective risk management and control strategies to facilitate the smooth progression of investment, merger, and acquisition activities.

Keywords: Medical investment, merger, and acquisition; Risk assessment; Control

Online publication: February 25, 2024

1. Introduction

The rapid development of the medical industry offers investors vast investment opportunities, yet it also presents numerous risks. Medical investment, merger, and acquisition represent significant forms of activity within this industry, and their risk assessment and control are paramount for both investors and medical institutions. This paper aims to delve into risk assessment and control, focusing on the characteristics and risks associated with medical investment, merger, and acquisition.

2. The characteristics of medical investment, merger, and acquisition

2.1. High risk level

The medical industry is inherently risky, and its unique nature results in medical investment, merger, and acquisition projects involving a multitude of risks. These projects typically demand substantial financial resources and entail prolonged return cycles, thus elevating the level of risk. Given the critical nature of the medical field, which directly impacts people's health and safety, significant investment is required for its advancement. However, the rapid evolution of medical technology necessitates short investment return cycles^[1]. Consequently, medical investment, merger, and acquisition often carry substantial risks. These projects typically require considerable financial investment, which is allocated towards acquiring assets, technologies, intellectual property, and other resources to enhance business scalability, efficiency, and cost-effectiveness. Nevertheless,

owing to the unique characteristics of the medical industry, such investments demand a high tolerance for risk and a long-term perspective ^[2,3].

2.2. Strong technical nature

The medical industry is highly technical, characterized by the continuous emergence of new technologies, medical institutions, practitioners, and drugs propelled by rapid advancements in medical technology. These innovations present boundless possibilities and opportunities for medical investment, merger, and acquisition. To address these matters, purchasers of medical investments must comprehensively grasp relevant technologies to select the most suitable technical solutions and seamlessly integrate them into existing medical institutions ^[4,5]. Introducing new technologies plays a pivotal role in medical investment, merger, and acquisition endeavors. By embracing these advancements, medical institutions can enhance their technological capabilities, elevate patient satisfaction, and augment their market share. However, in the adoption of new technologies, medical investment, merger, and acquisitions must thoroughly assess safety, reliability, and sustainability while mitigating technical risks and avoiding excessive investments ^[6].

Additionally, technology integration constitutes another critical aspect of medical investment, merger, and acquisition. Through integration, medical institutions can enhance their technical proficiency and optimize resource utilization. However, during this process, careful consideration must be given to the compatibility between different technologies, as well as the effectiveness and costs associated with integration, ensuring that integrated technologies fully leverage the advantages of medical institutions. Subsequently, technology application represents the final phase of medical investment, merger, and acquisition. By implementing these technologies, medical institutions can realize their practical application and value. Nevertheless, during the application phase, the involved parties must thoroughly assess the actual circumstances and requirements of medical institutions, opt for the most suitable technology application methods, and prioritize the safety and efficacy of technology application ^[7,8].

2.3. Management challenges

Medical investment, merger, and acquisition pose intricate and formidable challenges, necessitating solutions for governance structure, management proficiency, workforce composition, and operational efficacy within medical institutions. Given the unique nature of the medical industry, these endeavors encounter difficulties such as the quality of medical personnel and the modernization of medical equipment. The governance structure of medical institutions significantly influences their efficiency and management standards. This structure entails the delineation of responsibilities among decision-making bodies, managerial tiers, and oversight entities. In the context of medical investment, merger, and acquisition, attention must be paid to the ownership structure, ownership dynamics, and the composition of decision-making and managerial levels. Furthermore, it is imperative to consider stakeholder influence on healthcare institutions and devise strategies to safeguard institutional autonomy ^[9].

Management proficiency represents another pivotal challenge in medical investment, merger, and acquisition. It encompasses the operational acumen of medical institutions, including budgeting, decision analysis, personnel management, and customer satisfaction. In navigating medical investment, merger, and acquisition endeavors, emphasis should be placed on the management model, system, and adaptability to innovations. Additionally, the caliber of the management team and staff must be evaluated, along with strategies for integrating novel management principles and skills into medical institutions.

Workforce composition is a salient characteristic of medical institutions and a pertinent concern in medical investment, merger, and acquisition activities. It refers to the quantity, composition, and caliber of employees

within medical institutions, along with their roles and performance. Attention should be directed towards employee welfare, training initiatives, career development, and advancement opportunities. Moreover, the quality and competence of personnel must be considered, alongside efforts to foster conducive development environments and training prospects.

Medical investment, merger, and acquisition initiatives must also contend with the distinctive challenges inherent in the medical industry. The quality of medical personnel encompasses the professional skills and demeanor of healthcare workers, encompassing medical knowledge, technical proficiency, and bedside manner. Consequently, attention must be devoted to staff training, education programs, and credentialing efforts within medical institutions to uphold the standards of medical practice ^[10].

3. The risks of medical investment, merger, and acquisition

3.1. Market risk

The risks associated with medical investment, merger, and acquisition primarily encompass market, technical, management, and legal risks. Market risk stands out as one of the most critical factors influencing medical investment, merger, and acquisition, as fluctuations in the market can significantly impact investment returns. Within the realm of market risk, medical investment, merger, and acquisition initiatives may encounter challenges such as price fluctuations, intensified competition, and shifts in policies. These market dynamics can potentially impede investment returns; thus, it is essential to thoroughly evaluate market risks and devise corresponding mitigation strategies when undertaking medical investment, merger, and acquisition activities ^[11].

3.2. Technical risk

Technology risk represents another significant concern in medical investment, merger, and acquisition endeavors. This encompasses the possibility of unsuccessful technology adoption, integration, and application, all of which could jeopardize the success of investments and acquisitions. Technology-related setbacks may undermine the viability of medical ventures, ultimately affecting investment returns. Therefore, it is imperative to conduct comprehensive evaluations of technology to ensure alignment with the needs of medical institutions, accompanied by the development of robust technical risk management plans ^[12].

3.3. Management risk

Management risk constitutes yet another challenge in medical investment, merger, and acquisition initiatives. This encompasses issues such as mismanagement within healthcare institutions, staff attrition, and operational inefficiencies. Failure to effectively manage these risks may result in diminished operational efficiency within healthcare institutions, thereby impacting investment returns. Thus, it is crucial to thoroughly assess medical institutions to ascertain the presence of a stable management team and efficient operational capabilities during the medical investment, merger, and acquisition process.

3.4. Legal risk

Legal risk emerges as another significant concern in medical investment, merger, and acquisition activities. This encompasses compliance issues, contractual disputes, and intellectual property matters, among others. Legal challenges have the potential to derail medical investment, merger, and acquisition endeavors, consequently affecting investment returns. Therefore, thorough evaluations of legal risks are imperative to ensure that the operations of medical institutions adhere to legal and regulatory requirements ^[13].

4. Risk assessment and control of medical investment, merger, and acquisition

4.1. Market risk assessment

Within the medical market, investors must vigilantly monitor and effectively manage market risks. To achieve this, conducting thorough market research, staying abreast of market dynamics, and controlling the scale of investment are essential strategies to prevent overexposure to specific types of medical institutions.

4.2. Technical risk assessment

The advancement of medical technology plays a pivotal role in the medical market, making it imperative for investors to address technical risks. This entails staying informed about the trajectory of medical technology development, timely adoption of new technologies, and comprehensive evaluation to ensure their viability and feasibility.

4.3. Management risk assessment

Understanding the management capabilities, workforce quality, and medical equipment modernization within medical institutions is crucial for investors to identify and manage risks effectively. By gaining deep insights into medical institutions, investors can enhance their assessment of management risks and subsequently mitigate medical risks ^[14].

4.4. Legal risk assessment

The medical industry is governed by numerous laws and regulations, including those concerning medical malpractice and drug administration. Investors must familiarize themselves with these regulations, promptly address compliance issues, and take appropriate legal actions. Furthermore, addressing contract and intellectual property concerns in a timely manner is essential to prevent legal risks from materializing ^[15].

5. Conclusion

Medical investment, merger, and acquisition represent significant phenomena within the medical industry, offering opportunities for medical enterprises to enhance their scale, elevate their technological prowess, and optimize the allocation of medical resources. However, these endeavors also entail inherent risks and challenges. The critical factor in ensuring the seamless progression of medical investment, merger, and acquisition activities lies in effective risk assessment and control. This encompasses evaluating risks specific to the medical industry, devising efficient control measures, and bolstering supervision and management of investment, merger, and acquisition activities.

Disclosure statement

The author declares no conflict of interest.

References

- [1] Hong L, Chen S, Han F, 2015, Overseas Merger and Acquisitions, Organizational Control, and Investment Mode Selection –Based on Empirical Evidence from China. *Management World*, 2015(10): 40–53.
- [2] Zheng B, Shi H, 2020, A Research on the Decision-Making Method for Enterprise Merger and Acquisitions Considering the Synergetic Effect – Exemplified by 63 Biological and New Pharmaceutical Enterprises in Fuzhou.

Southeast Academic Research, 2020(2): 207–216.

- [3] Chen S-H, Zhang Z, Song B-S, 2020, What Kind of Failure is the Mother of Success? Evidence from the Impact of M&A Failure on Subsequent M&A Performance. *Business Management Journal*, 2020(4): 20–36.
- [4] Zhao Y, Qiao P, 2018, Do Motives for Cross-Border M&As Affect Ownership Choice? The Moderating Role of Firm Profitability. *Foreign Economics and Management*, 40(2): 51–67 + 137.
- [5] Jia P, 2017, The Development Trends and Situation Assessment of Chinese Enterprises Participating in Cross-Border Merger and Acquisitions – Based on the Practice of China’s “Going Global” Strategy. *Practice in Foreign Economic Relations and Trade*, 2017(7): 77–80.
- [6] Li Q, 2023, Financial Risk Control Strategies in Pharmaceutical Company Merger and Acquisitions. *Economic and Social Development*, 2023(2): 49–52.
- [7] Chang R, 2020, Risk Assessment and Prevention Research on Target Company Valuation in Corporate Merger and Acquisitions – A Case Study of QS Company’s Acquisition of LW Company. *Contemporary Accounting*, 2020(11): 151–152.
- [8] Kong N, 2022, Research on Financial Risk of Continuous Merger and Acquisitions of Pharmaceutical Enterprises Under Related Diversification Strategy – Take Zhongsheng Pharmaceutical as an Example, thesis, Northern University for Nationalities.
- [9] Dai D, 2020, Research on Financial Risk of M&A of Pharmaceutical Enterprises – Take China Resources Sanjiu Acquisition of Zhongyi Pharmaceutical as an Example, thesis, Chongqing University of Technology.
- [10] Chen S, 2019, Research on the Financial Risk and Control Strategy of the Merger and Acquisition of Pharmaceutical Enterprises. *Finance*, 2019(27): 97–98.
- [11] Wang X, 2021, A Case Study on the Financial Risk and Management Control of Merger and Acquisitions of Pharmaceutical Enterprises. *National Circulation Economy*, 2021(5): 55–57.
- [12] Li Z, 2019, Exploration of the Financial Risk Management Strategy of Merger and Acquisitions of Pharmaceutical Enterprises. *Modern Commerce and Trade Industry*, 2019(16): 115–116.
- [13] Li J, 2018, On the Financial Risk and Control of Merger and Acquisitions of Pharmaceutical Enterprises. *Knowledge Economy*, 2018(8): 85–86.
- [14] Xu F, 2020, Research on Financial Risk Analysis and Prevention of SDJC Pharmaceutical Company – Take PG Drug Source as an Example, thesis, Shandong University of Technology.
- [15] Liao L, 2020, Study on the Synergistic Effect of Pharmaceutical Companies Acquiring Hospitals – Take Jimin Pharmaceutical as an Example, thesis, Jinan University.

Publisher’s note

Bio-Byword Scientific Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.